(0)
- Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years -
- Winship Cancer Institute of Emory University s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose t
May 24, 2021 healthcare
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.
“Patients with EGFR Exon20 insertion+ mNSCLC have no proven targeted therapy options,” said Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University. “The updated r
E-Mail
IMAGE: HPV infection causes cells to undergo changes. If not treated these cells can, over time, become cancer cells. view more
Credit: National Cancer Institute
Today, doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents especially for the HPV vaccine. The pandemic also has exacerbated health disparities, leaving Black, Indigenous and other people of color; rural; and sexual minority adolescents at even greater risk for missed doses of this cancer prevention vaccine.
With new funding from the Veterans Affairs VA Lung Precision Oncology Program, Winship Cancer Institute of Emory University (Winship) will provide thoracic oncology expertise to help three VA medical centers expand access to high quality, disease altering lung cancer clinical trials to veterans in the Southeast.
This five-year project is supported by $5 million in funding. It involves six investigators from three VA medical centers and their cancer centers partners. They are: Charleston/MUSC Hollings Cancer Center (Nichole Tanner, MD, MSCR; John Wrangle, MD), Birmingham/O’Neal Comprehensive Cancer Center (Devika Das, MD; Mark Dransfield, MD), and Atlanta/Winship (Nicholas Maurice MD; Badi El Osta, MD).
New linear accelerator offers cancer patients high-tech treatment at Emory Decatur Hospital emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.